Investment in antimalarial drug development is bearing fruit
- Front-line antimalarial drugs (the artemisinin-based combination therapies) are failing in southeast Asia, making the need for novel antimalarials more pressing than ever. In The Lancet Infectious Diseases, two studies of DSM265, a plasmodium dihydroorotate dehydrogenase inhibitor, are reported. This novel antimalarial, discovered by a team at the University of Texas Southwestern, is in phase 2 clinical development for the prophylaxis and treatment of malaria.
- Publication status:
- Peer review status:
- Peer reviewed
(Version of record, pdf, 123.4KB)
- Publisher copy:
- Pubs id:
- Local pid:
- Deposit date:
- Copyright holder:
- Elizabeth Ashley
- Copyright date:
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access
article under the CC BY-NC-ND license.
If you are the owner of this record, you can report an update to it here: Report update to this record